Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | ERN1 | O75460 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 6/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721239 | 1.00 | CYP3A4 (0.49) | CYP3A4ERN1CYP2C9CYP2C19BRAF | |
| SCHEMBL29721342 | 0.90 | CYP3A4 (0.48) | CYP3A4ERN1CYP2C9CYP2C19BRAF | |
| SCHEMBL23458318 | 0.90 | CYP3A4 (0.48) | CYP3A4ERN1CYP2C9CYP2C19BRAF | |
| SCHEMBL24257006 | 0.90 | TSHR (0.45) | CYP3A4CYP2C9KDM4EALDH1A1SLC40A1 | |
| SCHEMBL1127143 | 0.85 | SLC40A1 (0.46) | CYP3A4ERN1BRAFNR1I2SLC40A1 | |
| SCHEMBL2192173 | 0.84 | CYP3A4 (0.45) | CYP3A4CYP2C9CYP2C19BRAFNR1I2 | |
| SCHEMBL23478182 | 0.81 | KMT2A (0.33) | CYP3A4 | |
| SCHEMBL26365883 | 0.80 | SLC40A1 (0.39) | CYP3A4ERN1CYP2C19BRAFNR1I2 | |
| SCHEMBL31264106 | 0.80 | SLC40A1 (0.39) | CYP3A4ERN1CYP2C19BRAFNR1I2 | |
| SCHEMBL1873673 | 0.79 | BRAF (0.49) | CYP3A4CYP2C9CYP2C19BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746419-B | N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors | 国家医疗保健研究所 | 2023-10-24 | — | — | CN | disclosed |
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-02 | — | — | US | disclosed |
| EP-4069692-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114746419-A | N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors | 国家医疗保健研究所 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-8415345-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo SmithKline LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | CYP3A4 25/4885ERN1 3675/4885CYP2C9 23/4885 |
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | BRAF, RAF1, NRAS | CYP3A4 4697/4885ERN1 559/4885CYP2C9 4543/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | CYP3A4 25/4885ERN1 3675/4885CYP2C9 23/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | CYP3A4 25/4885ERN1 3675/4885CYP2C9 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.